Dasinib 100 mg (Tablet)
Unit Price: ৳ 280.00 (2 x 10: ৳ 5,600.00)
Strip Price: ৳ 2,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dasatinib |
| Company | Drug international ltd |
Indications
- Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase
- Treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including Imatinib
- Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy
- Treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase
- Treatment of newly diagnosed Ph+ ALL in combination with chemotherapy
Pharmacology
- Inhibition of BCR-ABL, SRC family, c-KIT, EPHA2, and PDGFRβ kinases
- Active in leukemic cell lines representing variants of imatinib mesylate-sensitive and resistant disease
- Predicted to bind to multiple conformations of the ABL kinase
Absorption
- Maximum plasma concentrations observed between 0.5 to 6 hours following oral administration
- Increased mean AUC with a high-fat meal
Distribution
- Apparent volume of distribution is 2505 (CV% 93%)
- Approximately 96% binding to human plasma proteins in vitro
Elimination
- Mean terminal half-life of 3 to 5 hours
- Metabolized primarily by CYP3A4
- Excretion primarily via the feces
Dosage & Administration
- Starting dosage of 100 mg for chronic phase CML in adults
- Starting dosage of 140 mg for accelerated phase CML, myeloid or lymphoid blast phase CML, or Ph+ ALL in adults
- Dosage for pediatric patients based on body weight
Interaction
- Coadministration with strong CYP3A4 inhibitors may increase Dasinib concentrations
- Coadministration with strong CYP3A inducers may decrease Dasinib concentrations
- Coadministration with gastric acid reducing agents may decrease Dasinib concentrations
Contraindications
- Hypersensitivity to Dasatinib or any component of the formulation
Side Effects
- Myelosuppression
- Bleeding-related events
- Fluid retention
- Cardiovascular events
- Pulmonary arterial hypertension
- QT prolongation
- Severe dermatologic reactions
- Tumor lysis syndrome
- Effects on growth and development in pediatric patients
Pregnancy & Lactation
- Can cause fetal harm when administered to a pregnant woman
- Females of reproductive potential should avoid pregnancy during treatment
- Breastfeeding is not recommended during treatment and for 2 weeks after the final dose
Precautions & Warnings
- Severe thrombocytopenia, neutropenia, and anemia
- Bleeding risk with concomitant platelet function inhibitors or anticoagulants
- Fluid retention requiring supportive care measures
- Monitoring for cardiac dysfunction and pulmonary arterial hypertension
- Risk of QT prolongation
- Severe mucocutaneous dermatologic reactions
- Risk of tumor lysis syndrome
Overdose Effects
- Experience with overdose is limited
- Severe myelosuppression and bleeding reported in isolated cases
Therapeutic Class
- Targeted Cancer Therapy
Storage Conditions
- Store below 30°C in a dry place
- Protect from light
- Keep out of the reach of children